Iplex market forecast points to faster growth through 2035

The Business Research Company says the global Iplex market is in a rapid growth phase, driven by rising growth hormone deficiency cases, a larger pediatric population and higher healthcare R&D spending. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest through 2035.

Why it matters: - The Iplex market is tied to treatment for severe primary IGF-1 deficiency, a rare condition that affects growth in children. - Growth in this market reflects broader demand for specialized pediatric endocrine care and rare-disease therapies. - The report points to a commercial opportunity that depends on diagnosis rates, orphan drug support and recombinant protein production.

What happened: - The Business Research Company published its Iplex Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 5, 2026. - The report says the global Iplex market is gaining momentum as medical science advances and awareness of growth disorders rises. - The company identified North America as the largest regional market in 2025. - The company expects Asia-Pacific to post the fastest growth over the next several years. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Iplex, or mecasermin rinfabate, is a recombinant human insulin-like growth factor-1 combined with IGF binding protein-3. - Iplex is indicated for severe primary IGF-1 deficiency and is used to stimulate growth in children. - The drug stabilizes IGF-1 in its bound form, which supports cellular growth, metabolism and development while lowering hypoglycemia risk. - Historical growth in the market has been linked to better recognition of severe IGF-1 deficiency, limits in growth hormone therapies, recombinant IGF treatments, specialist-led protocols and orphan-drug incentives. - Expected future support for the market includes improved diagnosis of growth disorders, broader pediatric endocrinology services, greater caregiver awareness, continued orphan-drug support and advances in recombinant protein production. - Key trends include rare pediatric growth disorders, recombinant growth factor therapies, reduced hypoglycemia risk, expanded endocrinology care and long-term hormonal management in children. - Rising prevalence of growth hormone deficiencies is a main market driver. - Growth hormone deficiency occurs when the pituitary gland produces too little growth hormone, which can impair physical development in children and adults. - The report cites improved diagnostics, more awareness of endocrine disorders and higher rates of genetic mutations, tumors and traumatic brain injuries as contributors to rising GHD cases. - The report cites an October 2024 Cystic Fibrosis Trust update saying the UK cystic fibrosis registry had more than 11,318 people in 2023, with many older than 16 and many over 40. - The report uses that registry data to illustrate a growing and aging patient population that may face related hormonal deficiencies. - The expanding pediatric population is another demand driver. - The pediatric population spans birth to age 18 and requires specialized care for growth and development. - The report cites CDC data showing U.S. births rose 1% from 2023 to 2024 to 3,628,934. - The report says rising healthcare R&D investment is also supporting the market. - The report cites January 2025 NIH data showing the agency allocates most of its nearly $48 billion budget to medical research.

Between the lines: - The report frames Iplex demand as a niche but durable opportunity tied to rare disease treatment rather than broad primary care use. - The emphasis on diagnosis, specialist access and orphan-drug policy suggests market growth depends as much on healthcare systems as on drug performance. - The regional split implies mature demand in North America and more runway in Asia-Pacific as pediatric and endocrine care expands.

What's next: - The market’s next phase will likely depend on better identification of patients who qualify for IGF-1 therapy. - Continued investment in pediatric endocrinology and recombinant biologics could shape product availability and adoption. - The Business Research Company added new 2026 report features including TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The company is also offering a free sample and full report download through its website. More information - The full report is available here: the full report

The bottom line: - Iplex is a small rare-disease market with outsized growth tied to better diagnosis, more pediatric care and continued orphan-drug support.